Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-05-31 Purchase |
2024-06-04 6:06 pm |
Terns Pharmaceuticals Inc. | TERN | Yoon Seokho Bryan COO and General Counsel |
4,791 | $4.44 | $21,272 | 91,940 (Direct) |
View |
| 2024-05-31 Purchase |
2024-06-04 6:05 pm |
Terns Pharmaceuticals Inc. | TERN | Vignola Mark J. Chief Financial Officer |
4,791 | $4.44 | $21,272 | 91,940 (Direct) |
View |
| 2024-04-01 Sale |
2024-04-03 8:47 pm |
Terns Pharmaceuticals Inc. | TERN | Vivo Opportunity LLC Vivo Opportunity Fund Holdings L.P. Vivo Capital VIII LLC Vivo Capital Fund VIII L.P. Vivo Capital Surplus Fund VIII L.P. 10% Owner |
420,663 | $6.6487 | $2,796,859 | 268,573 (Indirect) |
View |
| 2023-11-30 Purchase |
2023-12-04 6:03 pm |
Terns Pharmaceuticals Inc. | TERN | Yoon Seokho Bryan COO and General Counsel |
743 | $3.78 | $2,809 | 18,399 (Direct) |
View |
| 2023-11-30 Purchase |
2023-12-04 6:03 pm |
Terns Pharmaceuticals Inc. | TERN | Vignola Mark J. Chief Financial Officer |
743 | $3.78 | $2,809 | 18,399 (Direct) |
View |
| 2023-05-31 Purchase |
2023-06-02 5:03 pm |
Terns Pharmaceuticals Inc. | TERN | Vignola Mark J. Chief Financial Officer |
9,997 | $1.41 | $14,096 | 17,656 (Direct) |
View |
| 2023-05-31 Purchase |
2023-06-02 5:03 pm |
Terns Pharmaceuticals Inc. | TERN | Yoon Seokho Bryan COO and General Counsel |
9,997 | $1.41 | $14,096 | 17,656 (Direct) |
View |
| 2023-05-31 Purchase |
2023-06-02 5:03 pm |
Terns Pharmaceuticals Inc. | TERN | Sundaram Senthil Vel Chief Executive Officer |
2,111 | $1.41 | $2,977 | 9,770 (Direct) |
View |
| 2022-11-30 Purchase |
2023-02-03 6:01 pm |
Terns Pharmaceuticals Inc. | TERN | Yoon Seokho Bryan COO and General Counsel |
3 | $1.41 | $4 | 367,659 (Direct) |
View |
| 2022-11-30 Purchase |
2023-02-03 6:01 pm |
Terns Pharmaceuticals Inc. | TERN | Vignola Mark J. Chief Financial Officer |
3 | $1.41 | $4 | 367,659 (Direct) |
View |
| 2022-11-30 Purchase |
2023-02-03 6:00 pm |
Terns Pharmaceuticals Inc. | TERN | Sundaram Senthil Vel Chief Executive Officer |
3 | $1.41 | $4 | 907,659 (Direct) |
View |
| 2022-12-23 Purchase |
2022-12-28 5:57 pm |
Terns Pharmaceuticals Inc. | TERN | ORBIMED ADVISORS LLC OrbiMed Capital GP VII LLC OrbiMed Asia GP III L.P. OrbiMed Advisors III Ltd OrbiMed Genesis GP LLC Director 10% Owner |
137,931 | $7.25 | $1,000,000 | 7,619,135 (Indirect) |
View |
| 2022-12-23 Purchase |
2022-12-28 5:46 pm |
Terns Pharmaceuticals Inc. | TERN | GORDON CARL L Director 10% Owner |
137,931 | $7.25 | $1,000,000 | 7,619,135 (Indirect) |
View |
| 2022-12-23 Purchase |
2022-12-23 5:48 pm |
Terns Pharmaceuticals Inc. | TERN | Vivo Opportunity LLC Vivo Opportunity Fund Holdings L.P. Vivo Capital VIII LLC Vivo Capital Fund VIII L.P. Vivo Capital Surplus Fund VIII L.P. 10% Owner |
758,620 | $7.25 | $5,499,995 | 6,657,992 (Indirect) |
View |
| 2022-12-23 Purchase |
2022-12-23 5:44 pm |
Terns Pharmaceuticals Inc. | TERN | Lu Hongbo Director |
758,620 | $7.25 | $5,499,995 | 4,340,212 (Indirect) |
View |
| 2022-11-23 Sale |
2022-11-28 4:56 pm |
Terns Pharmaceuticals Inc. | TERN | LAV Biosciences Fund V L.P. Hopewell Resources Holdings Ltd LAV Aqua Ltd Oriental Spring Venture Ltd 10% Owner |
1,500,000 | $5.5 | $8,250,000 | 1,816,460 (Indirect) |
View |
| 2022-09-07 Purchase |
2022-09-08 8:00 pm |
Terns Pharmaceuticals Inc. | TERN | Vivo Opportunity LLC Vivo Opportunity Fund Holdings L.P. Vivo Capital VIII LLC Vivo Capital Fund VIII L.P. Vivo Capital Surplus Fund VIII L.P. 10% Owner |
600,000 | $3.6 | $2,160,000 | 5,899,372 (Indirect) |
View |
| 2022-09-07 Purchase |
2022-09-08 8:00 pm |
Terns Pharmaceuticals Inc. | TERN | Lu Hongbo Director |
600,000 | $3.6 | $2,160,000 | 3,581,592 (Indirect) |
View |
| 2022-08-16 Purchase |
2022-08-18 5:00 pm |
Terns Pharmaceuticals Inc. | TERN | ORBIMED ADVISORS LLC OrbiMed Capital GP VII LLC OrbiMed Asia GP III L.P. OrbiMed Advisors III Ltd OrbiMed Genesis GP LLC Director 10% Owner |
3,690,000 | $2.42 | $8,929,800 | 1,072,400 (Indirect) |
View |
| 2022-08-16 Purchase |
2022-08-18 4:50 pm |
Terns Pharmaceuticals Inc. | TERN | GORDON CARL L Director 10% Owner |
3,690,000 | $2.42 | $8,929,800 | 1,072,400 (Indirect) |
View |
| 2022-08-12 Purchase |
2022-08-16 8:44 pm |
Terns Pharmaceuticals Inc. | TERN | Vivo Opportunity LLC Vivo Opportunity Fund Holdings L.P. Vivo Capital VIII LLC Vivo Capital Fund VIII L.P. Vivo Capital Surplus Fund VIII L.P. 10% Owner |
2,624,239 | $2.6599 | $6,980,244 | 6,799,372 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2024-06-10 Option Award |
2024-06-14 6:03 pm |
N/A 2034-06-09 |
Terns Pharmaceuticals Inc. | TERN | FELLOWS DAVID A Director |
32,000 | $0 | 32,000 (Direct) |
View |
| 2024-05-01 Option Award |
2024-05-02 5:29 pm |
N/A 2034-04-30 |
Terns Pharmaceuticals Inc. | TERN | Jung Melita Sun Chief Business Officer |
475,000 | $0 | 475,000 (Direct) |
View |
Ownership |
2024-03-19 7:26 pm |
N/A N/A |
Terns Pharmaceuticals Inc. | TERN | Kuriakose Emil Chief Medical Officer |
0 | $0 | 456,250 (Direct) |
View |
| 2024-03-01 Option Award |
2024-03-05 6:01 pm |
N/A N/A |
Terns Pharmaceuticals Inc. | TERN | Burroughs Amy L. Chief Executive Officer |
1,400,000 | $0 | 1,400,000 (Direct) |
View |
| 2024-01-23 Option Award |
2024-01-25 7:18 pm |
N/A N/A |
Terns Pharmaceuticals Inc. | TERN | Quigley Jill M. Sr. Advisor & Strategy Officer |
15,000 | $0 | 30,000 (Direct) |
View |
| 2024-01-23 Option Award |
2024-01-25 7:18 pm |
N/A 2034-01-22 |
Terns Pharmaceuticals Inc. | TERN | Yoon Seokho Bryan COO and General Counsel |
206,250 | $0 | 224,649 (Direct) |
View |
| 2024-01-23 Option Award |
2024-01-25 7:17 pm |
N/A 2034-01-22 |
Terns Pharmaceuticals Inc. | TERN | Vignola Mark J. Chief Financial Officer |
206,250 | $0 | 224,649 (Direct) |
View |
| 2024-01-23 Option Award |
2024-01-25 7:17 pm |
N/A 2034-01-22 |
Terns Pharmaceuticals Inc. | TERN | Quirk Erin President, Head of R&D |
225,000 | $0 | 225,000 (Direct) |
View |
| 2023-11-15 Option Award |
2023-11-17 6:10 pm |
N/A N/A |
Terns Pharmaceuticals Inc. | TERN | Quigley Jill M. Sr. Advisor & Strategy Officer |
15,000 | $0 | 15,000 (Direct) |
View |
| 2023-06-12 Option Award |
2023-06-14 7:02 pm |
N/A 2033-06-11 |
Terns Pharmaceuticals Inc. | TERN | Taylor Ann Elizabeth Director |
32,000 | $0 | 32,000 (Direct) |
View |
| 2023-06-12 Option Award |
2023-06-14 7:02 pm |
N/A 2033-06-11 |
Terns Pharmaceuticals Inc. | TERN | Tripuraneni Radhika Director |
32,000 | $0 | 32,000 (Direct) |
View |
| 2023-06-12 Option Award |
2023-06-14 7:02 pm |
N/A 2033-06-11 |
Terns Pharmaceuticals Inc. | TERN | Quigley Jill M. Director |
32,000 | $0 | 32,000 (Direct) |
View |
| 2023-06-12 Option Award |
2023-06-14 7:01 pm |
N/A 2033-06-11 |
Terns Pharmaceuticals Inc. | TERN | FELLOWS DAVID A Director |
32,000 | $0 | 32,000 (Direct) |
View |
| 2023-06-12 Option Award |
2023-06-14 7:01 pm |
N/A 2033-06-11 |
Terns Pharmaceuticals Inc. | TERN | GORDON CARL L Director 10% Owner |
32,000 | $0 | 32,000 (Direct) |
View |
| 2023-06-12 Option Award |
2023-06-14 7:01 pm |
N/A 2033-06-11 |
Terns Pharmaceuticals Inc. | TERN | Lu Hongbo Director |
32,000 | $0 | 32,000 (Direct) |
View |
| 2023-06-12 Option Award |
2023-06-14 7:01 pm |
N/A 2033-06-11 |
Terns Pharmaceuticals Inc. | TERN | KINDLER JEFFREY B Director |
32,000 | $0 | 32,000 (Direct) |
View |
| 2023-02-01 Option Award |
2023-02-03 6:01 pm |
N/A 2033-01-31 |
Terns Pharmaceuticals Inc. | TERN | Yoon Seokho Bryan COO and General Counsel |
360,000 | $0 | 367,659 (Direct) |
View |
| 2023-02-01 Option Award |
2023-02-03 6:01 pm |
N/A 2033-01-31 |
Terns Pharmaceuticals Inc. | TERN | Vignola Mark J. Chief Financial Officer |
360,000 | $0 | 367,659 (Direct) |
View |
| 2023-02-01 Option Award |
2023-02-03 6:00 pm |
N/A 2033-01-31 |
Terns Pharmaceuticals Inc. | TERN | Quirk Erin President, Head of R&D |
600,000 | $0 | 600,000 (Direct) |
View |
| 2023-02-01 Option Award |
2023-02-03 6:00 pm |
N/A 2033-01-31 |
Terns Pharmaceuticals Inc. | TERN | Sundaram Senthil Vel Chief Executive Officer |
900,000 | $0 | 907,659 (Direct) |
View |